Individuals with diabetes and cancer who use SGLT2 inhibitors are less likely to develop heart failure than those not taking the FDA-approved drug, latest research published in the British Medical Journal has revealed.
People with both diabetes and cancer are also expected to live longer if they use the prescription drug, the study has claimed.
During the experiment, the team of scientists analysed the health of more than 8,600 participants who were all living with the two conditions.
According to the findings, the people involved in the study using SGLT2 inhibitors (SGLT2i) were three times less likely to be admitted to hospital with heart failure compared to those not using them.
To read the entire study, click here.